KPTI (Karyopharm Therapeutics) Total Liabilities: $397.1 Mil (As of Mar. 2026)

What is Karyopharm Therapeutics Total Liabilities?

Karyopharm Therapeutics KPTI +0.63% 52 Total Liabilities is $397.1 Mil as of Mar. 2026. GuruFocus rates KPTI with a GF Score™ of 52/100 and a GF Value™ of $6.34 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Karyopharm Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was $397.1 Mil.

Karyopharm Therapeutics's quarterly Total Liabilities increased from Sep. 2025 ($365.49 Mil) to Dec. 2025 ($401.34 Mil) but then declined from Dec. 2025 ($401.34 Mil) to Mar. 2026 ($397.06 Mil).

Karyopharm Therapeutics's annual Total Liabilities declined from Dec. 2023 ($376.64 Mil) to Dec. 2024 ($350.44 Mil) but then increased from Dec. 2024 ($350.44 Mil) to Dec. 2025 ($401.34 Mil).

Karyopharm Therapeutics Total Liabilities Related Terms

Karyopharm Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Karyopharm Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Karyopharm Therapeutics Total Liabilities Chart

Karyopharm Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Liabilities

Get a 7-Day Free Trial

384.98

374.83

376.64

350.44

401.34

Karyopharm Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Liabilities	Get a 7-Day Free Trial															333.60	343.81	365.49	401.34	397.06

52GF Score

Karyopharm Therapeutics Inc KPTI

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Karyopharm Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Karyopharm Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	92.06	+	(211.628	+	25.316
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	72.338	+	0	+	0)
	=	401.3

Total Liabilities	=	Total Assets (A: Dec. 2025 )	-	Total Equity (A: Dec. 2025 )
	=	108.416	-	-292.926
	=	401.3

Karyopharm Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	117.302	+	(197.624	+	9.799
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	72.338	+	0	+	0)
	=	397.1

Total Liabilities	=	Total Assets (Q: Mar. 2026 )	-	Total Equity (Q: Mar. 2026 )
	=	131.417	-	-265.646
	=	397.1

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of $397.1 Mil mean?

Karyopharm Therapeutics (KPTI) has a Total Liabilities of $397.1 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Karyopharm Therapeutics and its competitors.

Is Karyopharm Therapeutics' Total Liabilities too high?

Karyopharm Therapeutics' current Total Liabilities is $397.1 Mil. Overall, Karyopharm Therapeutics has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Karyopharm Therapeutics' Total Liabilities compare to CHRS and TARA?

Karyopharm Therapeutics' Total Liabilities of $397.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Biotechnology company?

A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Karyopharm Therapeutics and its competitors. Karyopharm Therapeutics's current Total Liabilities is $397.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Karyopharm Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Karyopharm Therapeutics (KPTI) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.34, compared to a current price of $9.60 — trading 51.4% above its estimated fair value. The current Total Liabilities is $397.1 Mil. Karyopharm Therapeutics' overall GF Score™ is 52/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For Karyopharm Therapeutics (KPTI), the current Total Liabilities is $397.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Karyopharm Therapeutics (KPTI) Overvalued in 2026?

Based on GuruFocus' analysis, Karyopharm Therapeutics stock appears to be overvalued. The current stock price of $9.60 is trading 51.4% above its estimated GF Value™ of $6.34. GuruFocus considers Karyopharm Therapeutics to be Significantly Overvalued.

Key valuation signals for KPTI:

Total Liabilities: $397.1 Mil
GF Value™: $6.34 vs. price of $9.60 (51.4% above fair value)
GF Score™: 52/100 with 8 warning signs

No single metric tells the full story. See the KPTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Karyopharm Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies CHRS TARA CNTN RNA AVXL QTTB SLGL FATE CAMP CDXS VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges 25K0:Germany

Address 85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459

Website https://www.karyopharm.com

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).

52GF Score

Get the complete analysis for KPTI

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.60

Price

$6.34

GF Value

View KPTI Analysis

See Total Liabilities data for all stocks →